A comparison of the prevalence of prenatal alcohol exposure obtained via maternal self-reports versus meconium testing: a systematic literature review and meta-analysis by Shannon Lange et al.
Lange et al. BMC Pregnancy and Childbirth 2014, 14:127
http://www.biomedcentral.com/1471-2393/14/127RESEARCH ARTICLE Open AccessA comparison of the prevalence of prenatal
alcohol exposure obtained via maternal
self-reports versus meconium testing:
a systematic literature review and meta-analysis
Shannon Lange1,2, Kevin Shield1,3, Gideon Koren4,5,6,7,8, Jürgen Rehm1,2,3,9 and Svetlana Popova1,2,3,10*Abstract
Background: Maternal self-reports, used for the detection of prenatal alcohol exposure (PAE), may lack validity,
necessitating the use of an objective biomarker. The detection of fatty acid ethyl esters (products of non-oxidative
ethanol metabolism) in meconium has been established as a novel biomarker of PAE. The purpose of the current
study was to compare the prevalence of PAE as reported via maternal self-reports with the results of meconium
testing, and to quantify the disparity between these two methods.
Methods: A systematic literature search for studies reporting on the prevalence of PAE, using maternal self-reports
in combination with meconium testing, was conducted using multiple electronic bibliographic databases.
Pooled prevalence estimates and 95% confidence intervals (CI) were calculated based on eight studies, using the
Mantel-Haenszel method, assuming a random effects model. A random effects meta-regression was performed to
test for a difference.
Results: The pooled prevalence of PAE as measured by meconium testing was 4.26 (95% CI: 1.34-13.57) times the
pooled prevalence of PAE as measured by maternal self-reports. Large variations across the studies in regard to the
difference between estimates obtained from maternal self-reports and those obtained from meconium testing were
observed.
Conclusions: If maternal self-reports are the sole information source upon which health care professionals rely, a
number of infants who were prenatally exposed to alcohol are not being recognized as such. However, further research
is needed in order to validate existing biomarkers, as well as discover new biomarkers, for the detection of PAE.
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Prenatal alcohol exposure (PAE) may cause a number of
health complications for the mother and the developing
fetus, including Fetal Alcohol Spectrum Disorder (FASD).
As a “spectrum” disorder, FASD encompasses a broad
array of physical defects, cognitive, behavioural, emotional,
and adaptive functioning deficits, as well as congenital
anomalies, such as malformations and dysplasia of the* Correspondence: lana.popova@camh.ca
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unless otherwise stated.cardiac, skeletal, renal, ocular, auditory, and other systems
[1]. These impairments are likely to have lifelong implica-
tions, which result in a significant economic burden for
any society. However, the burden of FASD is not measur-
able by cost alone, the lifelong hardships faced by these chil-
dren and their families are also of considerable importance.
Identification of infants exposed to alcohol in utero is
crucial, as it can lead to close monitoring of his/her devel-
opment, facilitate early FASD diagnosis, and implement
timely interventions, if necessary. Early interventions
have long-term benefits for a child with FASD and can
potentially reduce the occurrence of secondary disabil-
ities including poor school performance, addictions,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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dependent living, legal issues, and incarceration [2].
Early FASD diagnosis and providing a stable and nurt-
uring environment for the child have been shown to
improve outcome and decrease the risk of secondary
disabilities by up to fourfold [2,3].
Furthermore, screening of neonates for PAE and early
FASD diagnosis can prevent subsequent alcohol-exposed
births by providing appropriate interventions, treatment,
counselling, and support for birth mothers with unrec-
ognized alcohol dependence and mental health problems
[1,4]. Appropriate screening strategies may also facilitate
early recognition and intervention for affected siblings.
In order for an infant to be diagnosed with an FASD,
PAE needs to be confirmed (with the exception of Fetal
Alcohol Syndrome (FAS), which can be diagnosed with-
out PAE confirmation). This can be problematic as ma-
ternal self-report data are often under-reported for a
variety of reasons (e.g., social desirability bias, recall bias,
and/or fear that the child may be taken away). Thus, the
detection of PAE in neonates by maternal self-report
was shown to be unreliable [5]; thereby necessitating
the use of an unbiased biomarker to identify those at
risk for FASD.
The use of biological markers has emerged as a practical
method for the identification of PAE [6,7]. Currently, there
are several measurable biomarkers available for detecting
PAE (i.e., fatty acid ethyl esters [FAEE], ethylglucuronide
[EtG], ethlysulphate [Ets], and phosphatidylethanol [PEth])
in a range of neonatal matrices (e.g., hair, meconium, blood,
placenta, and umbilical cord) [6,8-10]. FAEE in meconium
and hair is currently the most commonly used tool to esti-
mate the prevalence of PAE [8]. The validity of the other
biomarkers, listed above, remains to be established in neo-
natal matrices [8].
The detection of FAEE, products of non-oxidative etha-
nol metabolism, above laboratory cut-points in meconium,
has been repeatedly established as a novel biomarker of
fetal ethanol exposure in the second and third trimesters
of pregnancy [11-19]. Meconium testing for FAEE is a val-
idated method for detecting PAE; it has been shown to
have high sensitivity (84.2%) and specificity (83.3%) [11].
Meconium comprises the neonate’s first several bowel
movements, identified most commonly by its dark green/
black colour and lack of odour. It is generally agreed upon
that meconium formation begins at approximately 12
weeks of gestation (i.e., at the end of the first trimester),
when fetal swallowing of amniotic fluid is initiated [20,21];
however, some researchers have suggested formation be-
gins even later (up to 20 weeks of gestation) [22-26]. FAEE
do not cross the human placenta, causing meconium to
serve as a reservoir of fetal chemical exposures during the
second and third trimesters of pregnancy. Thus, the pres-
ence of FAEE in the meconium is a true reflection of fetalethanol metabolism [14]. Cumulative meconium FAEE
concentrations exceeding 2.0 n▪mol/g, the internationally
accepted cut-point [13], may be indicative of seven or
more drinks per week or five or more drinks per occasion
(i.e., “binge” drinking) [15,27].
The purpose of the current study was to compare the
prevalence of PAE, as reported via maternal self-reports,
with the results of meconium testing (the most com-
monly used laboratory screening method for estimating
the prevalence of PAE, with proven accuracy), and to
quantify the disparity between these two methods.
Methods
The systematic literature review and meta-analyses were
conducted and reported according to the standards set
out in Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA; http://www.prisma-statement.
org/) [28].
Ethics statement
The current study utilized secondary data reported on
the aggregate level, which is readily available in the lit-
erature; therefore, it was not necessary to obtain re-
search ethics approval.
Literature search
A literature search was performed to identify published
studies that have estimated the prevalence of PAE at any
level and at any point of time during pregnancy using
maternal self-reports and meconium testing.
The search was conducted in multiple electronic biblio-
graphic databases, including: Ovid MEDLINE, PubMed,
EMBASE, Web of Science (including Science Citation
Index, Social Sciences Citation Index, Arts and Human-
ities Citation Index), BIOSIS, PsycINFO, Social Work Ab-
stracts, Scopus, and Google Scholar. The search was
conducted using multiple combinations of the following
key words: 1) alcohol, ethanol, FASD, FAS, pFAS, ARND,
ARBD, PAE; 2) consum*, drink*; 3) maternal, mother,
primigravida, wom*n; 4) pregnan*, prenatal; 5) biomarker,
fatty acid ethyl ester, meconium (analysis), self-report;
and 6) prevalence, frequenc*, occurrence.
In addition, manual reviews of the content pages of
the major epidemiological journals were conducted, as
well as citations in the relevant articles. The search was
not limited geographically or by language of publication
and was conducted on studies published before January
2013, inclusively.
Eligibility criteria
Articles were retained if they met the following eligibility
criteria: i) consisted of original, quantitative research on
human participants published in a peer-reviewed journal;
and ii) obtained a measurement of maternal alcohol use
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tionnaire, etc.) in combination with meconium testing
for FAEE with a pre-defined cumulative cut-point (this
criterion was used as a quality control measure and was
necessary for comparability purposes).
It must be recognized that because of the latter inclu-
sion criterion, the pooled estimates obtained for mater-
nal self-reports and for meconium testing cannot be
used to make any inferences on their own; however, they
can be used to quantify the pooled difference between
these two methods of ascertainment (the purpose of the
current study).
Studies were first screened using titles and abstracts;
of those retained, the eligibility criteria were applied, and
preference was given to full-text peer reviewed journal
publications in all cases.
Data extraction
One member of the study team independently extracted
the data from the available articles, while a second inves-
tigator checked table entries for accuracy against the ori-
ginal articles. All discrepancies were reconciled by team
discussion. The following data were extracted from each
article, wherever available: the country in which the
study was conducted (as well as the specific provinces,
territories or states, if such information was available),
the year(s) of the study (i.e., the year(s) in which data
collection took place), the sample size, maternal age, the
prevalence of PAE via self-reported data, the assessment
tool used to obtain self-reported alcohol use, the trimes-
ter during which alcohol was consumed, the frequency
of alcohol use, the prevalence of PAE via meconium test-
ing, and the cumulative FAEE cut-point used.
Statistical analysis
To combine the prevalence estimates of PAE as measured
by maternal self-reports and by meconium testing, meta-
analyses were performed using the Mantel-Haenszel
method, assuming a random-effects model [29]. Before
performing the meta-analyses, prevalence estimates were
transformed using a double arcsine transformation so
that the data followed a normal distribution (an assump-
tion needed when statistically combining estimates) [30].
Heterogeneity between studies was assessed using the
Cochrane Q-test and the I2 statistic [31,32]. Results of the
meta-analyses were displayed using Forest plots. Publica-
tion bias was assessed using a ranked correlation test [33],
and by employing a weighted regression test [34]; how-
ever, given that the prevalence estimates are unlikely to be
affected by publication bias [35], if present, publication
bias would not be adjusted for.
To test for a difference in the prevalence estimates of
PAE as measured by maternal self-reports and those ob-
tained by meconium testing, a random effects meta-regression (using a logit regression [using log odds trans-
formed prevalence estimates]) was performed. The correl-
ation between estimates from the same study was corrected
for in the meta-regression model. The prevalence estimates
as reported by Manich and colleagues [36] were excluded
from the meta-regression, as the standard error of the log
odds transformed prevalence estimates of 0 are undefined.
All statistics were performed using STATA version
11.2.
Results
Characteristics of the included studies
Initially, the electronic search yielded a total of 839 pub-
lications regarding the prevalence of PAE, measured
using maternal self-reports and meconium testing, when
using the key words specified above (there were no arti-
cles identified through other sources - i.e., the manual
search). After removing 501 duplicate articles, a total of
338 articles were screened using titles and abstracts.
Fifty-six full-text articles were retrieved for further con-
sideration, 47 of which were subsequently excluded. A
total of 9 articles were retained and selected for data
extraction.
A schematic diagram of the search strategy is depicted
in Figure 1.
Nine studies on the prevalence of PAE, obtained via ma-
ternal self-reports and meconium testing (Hutson et al.
[37] and Magri et al. [38,39] were published in iteration,
and Derauf et al. [40,41] are dual publications), were iden-
tified from the literature. Data on the prevalence of PAE,
obtained via maternal self-reports and meconium testing,
were available from only six countries: Canada [15,42],
Germany [43], Italy [44,45], Spain [36,44,46], Uruguay
[37-39], and the United States [40,41].
Please see Table 1 for the characteristics of the studies
available on the prevalence on PAE obtained via mater-
nal self-reports and meconium testing.
With respect to meconium testing, eight of the identi-
fied studies used the internationally accepted cumulative
FAEE cut-point of 2 n▪mol/g, while Derauf et al. [40,41]
used 50 n▪g/g, which is approximately 10 times lower.
Based on the self-reported data, the prevalence of PAE
ranged from 0% (in Spain [36]) to 36.8% (in Uruguay
[37-39]). In comparison, based on the meconium testing
data, the prevalence of PAE ranged from 2.5% (in Canada
[15]) to 45.0% (in Spain [46]; Table 1). The prevalence of
PAE, obtained via meconium testing, ranged from 1.2
times (in Uruguay [37-39]) to 43 times higher (in Germany
[43]) than that obtained via maternal self-reports (Table 1
and Figure 2).
In one of the studies from Italy [45], which investi-
gated the prevalence of PAE across seven sites, four of
the sites reported a higher prevalence using maternal
self-reports compared to meconium testing, while three
Records identified through database 
searching 
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Figure 1 Flow diagram depicting the search strategy employed.
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ing, compared to maternal self-reports (Figure 3). As a
result, in Pichini et al. [45] the pooled prevalence of PAE
based on maternal self-reports across all seven sites was
1.4 times higher than the prevalence obtained via meco-
nium testing.
Pooled prevalence of PAE obtained via maternal
self-reports versus meconium testing
Eight studies were included in the meta-analysis. The
study by Derauf et al. [40,41] was excluded because the
cumulative FAEE cut-point used in this study was about
10 times lower than the cumulative FAEE cut-points
used in the other studies (2 n▪mol/g; see Table 1).
The meta-analysis revealed that the pooled prevalence
of PAE obtained by maternal self-reports was 4.5% (95%
confidence interval (CI): 0.1% to 15.1%; see Figure 4 for
Forest plot). Tests demonstrate that heterogeneity in
these estimates was present (Q(8) = 751.70, p = 0.000;
I2 = 98.9%, p = 0.000). The pooled prevalence of PAE ob-
tained by meconium testing was 18.9% (95% CI: 8.4%
to 33.9%; see Figure 5 for Forest plot). Tests demon-
strate that heterogeneity in these estimates was also
present (Q(8) = 714.67, p = 0.000; I
2 = 98.9%, p = 0.000).
Begg’s rank correlation test (p = 0.602 and p = 0.602 forthe meta-analysis of estimates of PAE as obtained from
maternal self-reports and meconium testing, respect-
ively) [33] and Egger weighted regression test (p = 0.493
and p = 0.807 for the meta-analysis of estimates of PAE
as obtained from maternal self-reports and meconium
testing, respectively) [34] both indicated that publication
bias was not present for these meta-analyses (see Figure 6
and Figure 7 for Funnel plots). Based on the estimates
presented above, meconium testing resulted in values
14.4% higher than maternal self-reports.
The meta-regression using log odds transformed
prevalence estimates indicated that the prevalence of
PAE as measured by meconium testing was 4.26 (95%
CI: 1.34 to 13.57) times the prevalence of PAE as mea-
sured by maternal self-reports (p = 0.021; see Table 2).
Discussion
The prevalence estimates of PAE will be, on average,
four times higher when using meconium testing com-
pared to the prevalence estimates obtained using mater-
nal self-reports; however, it is not currently feasible to
use meconium testing to screen every newborn or to im-
plement a universal meconium testing screening pro-
gram. There are also legal and ethical issues surrounding
meconium testing and its use as a universal screening
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AUDIT: Alcohol Use Disorders Identification Test; FAEE: fatty acid ethyl esters; n/a: not available; SES: socio-economic status.
aLevels of increased sensitivity may not total percentage figures obtained via meconium testing divided by percentage figures obtained via self-reports due to rounding errors.
bPichini et al. [44] reported results for two study sites (Italy and Spain).
cReported “daily” consumption.
dHutson et al. [37] and Magri et al. [38,39] were published in iteration.
eDerauf et al. [40,41] are dual publication.



















Figure 2 The prevalence of prenatal alcohol exposure obtained using maternal self-reports versus meconium testing and the pooled
prevalence estimate.
Lange et al. BMC Pregnancy and Childbirth 2014, 14:127 Page 6 of 11
http://www.biomedcentral.com/1471-2393/14/127tool (see Dickens [49]), which need to be resolved before
implementation of such a screening program takes place.
Thus, a maternal self-report method is the most widely
used at the present time.
The current study has limitations due to the lack of
consistency across studies with respect to maternal self-
report data. For instance, the studies used different in-
struments/methods to obtain the self-reported data, each
with its own sensitivity and specificity. Furthermore,
only one study [45] had provided a breakdown by fre-
quency of alcohol use: “daily”, “weekly”, and “monthly”
(however, the amount consumed was not reported). In
addition, the majority of studies did not specify the timeFigure 3 The prevalence of prenatal alcohol exposure obtained using
in Italy. Footnote. Source: Pichini et al. [45].period captured by the exposure assessment, and as a re-
sult, it cannot be said definitively that the maternal self-
reported data is reflective of the same time period as the
meconium testing data (which detects alcohol use in the
second and third trimesters only).
Mecounium testing also has several limitations. Due to
the inability of meconium testing to ascertain PAE during
the first trimester and to “detect” if pregnant women con-
sumed less than seven drinks per week and/or did not
practice “binge” drinking (five or more drinks per occa-
sion) during the second and third trimesters of pregnancy,
the prevalence of PAE obtained using this method is likely
to be an underestimate and, thus, the pooled differencematernal self-reports versus meconium testing across seven sites
Figure 4 Forest plot of the prevalence of prenatal alcohol exposure as measured by maternal self-reportsa. Footnote. CI: confidence
interval. a The size of the box around the point estimate is representative of the weight of the estimate used in calculating the aggregated
point estimate.
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ever, a positive meconium test (i.e., above the cumulative
FAEE cut-point) indicated heavy drinking in the second
and third trimesters. In countries where the majority
of women are aware of the adverse effects of alcoholFigure 5 Forest plot of the prevalence of prenatal alcohol exposure a
a The size of the box around the point estimate is representative of the weconsumption on the developing fetus (e.g., Australia and
Canada [50,51]), a positive meconium test likely indicates
continuous drinking during pregnancy and thus, alcohol
dependence; therefore, meconium testing can be said to
identify the most at-risk group of neonates.s measured by meconium testinga. Footnote. CI: confidence interval.
ight of the estimate used in calculating the aggregated point estimate.
Figure 6 Funnel plot of the prevalence of prenatal alcohol exposure as measured by maternal self-reports.
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methods for testing meconium for the presence of FAEE
(e.g., in the extraction methods used, and in the analytical
strategies employed), which affect the PAE prevalence esti-
mates obtained [52]. Furthermore, the association between
level of alcohol consumption and the level of FAEE is diffi-
cult to ascertain due to individual differences of both the
mother and the fetus [52].
Given the limitations of meconium testing, one should
err on the side of caution when screening for PAE, as
there are potentially serious consequences of both falseFigure 7 Funnel plot of the prevalence of prenatal alcohol exposurepositive and false negative results. This is especially import-
ant when a “positive” test is used for any other purpose
than to identify individuals at-risk and in need of interven-
tion, such as when PAE is used as an alternative explan-
ation for poor birth outcomes in medical malpractice
claims. A “positive” meconium test result could also lead
to increased contact with child protective services in some
countries. Accordingly, there is a need for research that
can lead to improvements in the sensitivity and specificity
of meconium testing so that a universal standard can be
definitively established.as measured by meconium testing.
Table 2 Results of the meta-regression testing for a difference in the prevalence estimates of prenatal alcohol exposure
as measured by maternal self-reports and those obtained by meconium testing





Log-odds model 1a Meconium testing (as compared
to maternal self-reports)
4.41 0.82 23.76 0.08
Log-odds model 2b Meconium testing (as compared
to maternal self-reports)
4.26 1.34 13.57 0.02
aNot controlling for between study differences in measurement.
bControlling for between study differences in measurement.
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mates of the prevalence of PAE (regardless of the method
of detection) vary across countries, as well as within coun-
tries. Furthermore, large variations in the estimates of
PAE as measured by maternal self-reports were observed
when compared to estimates of PAE obtained from meco-
nium testing. Between country variations in the preva-
lence of PAE likely stem from differences in maternal
drinking behaviours, as well as from political, ideological,
cultural, and legal differences between countries. As dis-
cussed in a recent study by Drabble and colleagues [53],
countries vary considerably in the quality and type of
public messaging in terms of levels of political attention,
responsiveness of governments, and the information
relayed to the public regarding alcohol and pregnancy. For
countries in which there is heightened political attention,
responsiveness, and public messaging regarding alcohol
use during pregnancy, there is an increased understand-
ing of the risk associated with alcohol consumption and
pregnancy, and consequently, a lower observed preva-
lence of PAE.
Differences in ideological and cultural conditions be-
tween countries can also influence both the prevalence
of alcohol use during pregnancy and the accuracy of ma-
ternal self-reports [53]. For example, the social accept-
ability of alcohol use among women influences the
stigmatization of women who do consume alcohol, espe-
cially during pregnancy [53]. Thus, in those countries
where alcohol consumption by women is not socially ac-
ceptable, women are less likely to report their use of al-
cohol during pregnancy. This could explain the results
reported for Uruguay [37-39], where maternal self-
reports were not that different from the results of the
meconium testing, and could explain the results from
some study sites in Italy [45], where maternal self-
reports yielded higher prevalence estimates compared to
meconium testing. It is possible that in Uruguay and in
Italy alcohol consumption by women is less stigmatized
when compared to other countries, and thus, women are
more likely to accurately report their alcohol consump-
tions during pregnancy (Magri R 2013, personal commu-
nication, May 11). The results from Uruguay and Italy
may be explained further by the potential that “low/moderate” levels of alcohol consumption were not “de-
tected” by meconium testing, whereas these levels can
be measured by maternal self-reports. Furthermore, a
lack of public awareness may exist in Uruguay and in
Italy of the deleterious effects of alcohol on a develop-
ing fetus, and as a consequence, women in these coun-
tries may be more willing to reveal alcohol use during
pregnancy [53].
Finally, laws concerning alcohol use during pregnancy
may impact variations in self-reported PAE. In Canada,
for example, women are not held legally responsible for
prenatal injuries, as holding a woman legally responsible
in these circumstances is considered to a violation of her
fundamental rights [49]. Therefore, an absence of legal
consequences of PAE may cause women to be more will-
ing to disclose their alcohol use during pregnancy.Conclusions
Based on the results of this study, health care profes-
sionals should be aware of the under-reporting of PAE
by maternal self-reports. If maternal self-reports are not
adjusted for under-reporting, a number of infants pre-
natally exposed to alcohol will not being recognized as
such. Although meconium testing provides more accur-
ate data, this paper advocates for the use of meconium
testing in addition to maternal self-reports when testing
for PAE. However, given that meconium testing cannot
determine exposure in the first trimester, further re-
search is needed in order to discover new and validate
existing biomarkers for the detection of PAE. As indi-
cated above, there are a number of biomarkers available
for detecting PAE in a range of neonatal matrices. These
biomarkers need to be further explored and the accuracy
(i.e., sensitivity and specificity) of the methods employed
needs to be established; however, some preliminary re-
sults appear promising (see for example, Bakhireva et al.
[54], Matlow et al. [55], and Shukla et al. [56]).
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